In Vivo Model Development for Eosinophilic Esophagitis

Protheragen offers comprehensive in vivo animal model development services for Eosinophilic Esophagitis (EoE), supporting drug discovery and translational research. Our team leverages cutting-edge methodologies and validated mouse models to evaluate candidate therapeutics, providing clients with robust and reproducible preclinical data tailored to their research needs.

Eosinophilic Esophagitis is a chronic, immune-mediated esophageal disorder with increasing prevalence worldwide. Accurate animal models are essential for unraveling disease mechanisms and evaluating novel interventions. Protheragen utilizes Mus musculus (mouse) models, including the Balb/c strain and transgenic lines, which closely recapitulate the immunopathology and clinical features observed in human EoE. These models enable researchers to study allergen-induced, chemical, and genetic contributors to EoE, facilitating the translation of preclinical findings to clinical applications.

Dietary (Allergen-Induced) Models

This model type employs dietary administration of specific allergens, such as peanut extract, to Balb/c mice to induce EoE-like pathology. The methodology involves sensitizing and challenging mice with the allergen, resulting in esophageal eosinophilia, tissue remodeling, and Th2 cytokine profiles similar to those seen in patients. Key advantages include high translational relevance, reproducibility, and suitability for testing food allergen-specific therapies. Primary research applications encompass assessment of immunomodulatory treatments, allergen desensitization strategies, and mechanistic studies of food-induced EoE.

Chemically-Induced Models

Chemically-induced models utilize agents such as oxazolone to provoke esophageal inflammation and eosinophil infiltration in mice. The protocol typically involves topical or systemic administration of the chemical sensitizer, triggering immune responses that mirror certain aspects of human EoE. Advantages of this model include rapid disease induction, control over severity, and applicability for screening anti-inflammatory compounds. These models are primarily used for evaluating therapeutic efficacy, dissecting inflammatory pathways, and studying acute-onset EoE.

Genetic (Transgenic) Models

Genetic models involve the use of transgenic mice, such as IL-5 overexpressing lines, to spontaneously develop EoE-like features. These models provide insights into the role of specific cytokines and immune pathways in disease pathogenesis. The methodology centers on the stable genetic modification of mice to mimic the chronic immune activation observed in EoE patients. Key advantages include the ability to study long-term disease progression and the effects of targeted genetic interventions. They are ideal for research focused on the molecular underpinnings of EoE and the evaluation of biologics targeting cytokine signaling.

Protheragen delivers a full-spectrum EoE animal model service, encompassing model selection, induction, therapeutic administration, sample collection, and comprehensive data analysis. Key efficacy endpoints include esophageal eosinophil counts, histopathological scoring, cytokine profiling (e.g., IL-5, IL-13), tissue remodeling assessment, and symptomatology evaluation. Our analytical capabilities feature advanced immunohistochemistry, flow cytometry, ELISA, and gene expression analysis. Rigorous quality control measures are implemented at every stage, including standardized protocols, validated reagents, and reproducibility checks, ensuring reliable and high-quality data for your preclinical programs.

By partnering with Protheragen, you gain access to scientifically validated EoE models, expert technical support, and a commitment to excellence that accelerates your therapeutic development. Our integrated approach streamlines your research workflow, reduces risk, and enhances translational value. Contact us today to discuss your EoE project and discover how Protheragen can help advance your research objectives.